Organization
Fraunhofer Institute for Translational Medicine & Pharmacology ITMP
1 abstract
Abstract
BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMALOrg: UCB Pharma, Fraunhofer Institute for Translational Medicine & Pharmacology ITMP,